Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May;32(5):543-4.
doi: 10.1038/aps.2011.58. Epub 2011 May 2.

Nanodiamond delivery circumvents tumor resistance to doxorubicin

Xiao-wei Ma  1 , Yu-liang Zhao, Xing-jie Liang
Affiliations

Nanodiamond delivery circumvents tumor resistance to doxorubicin

Xiao-wei Ma et al. Acta Pharmacol Sin. 2011 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
ND delivery of Dox inhibits tumor growth in murine liver tumor models and mammary carcinoma model. (A) Images of livers/tumors from PBS, Dox, ND, or NDX treated LT2-Myc liver tumor bearing mice. (B) Representative images of excised tumors from PBS, Dox, or NDX treated 4T1 mammary tumor bearing mice. (C) Kaplan-Meier survival plot for LT2-Myc mice treated with PBS (n=5), Dox (100 mg) (n=8), or NDX (100 mg of Dox equivalent) (n=7) by tail vein injection every 7 d. *P<0.03; **P<0.06. (D) Kaplan-Meier survival plot for 4T1 mice treated with PBS (n=7), Dox (100 mg) (n=10), NDX (100 mg of Dox equivalent) (n=10), Dox (200 mg) (n=5), or NDX (200 mg of Dox equivalent) (n=5) by tail vein injection every 6 d. *P<0.003. Reprinted with permission from AAAS: Science Translational Medicine, copyright 2011.
See this image and copyright information in PMC

References

    1. Giaccone G, Linn SC, Pinedo HM. Multidrug resistance in breast cancer: mechanisms, strategies. Eur J Cancer. 1995;31A:S15–7. - PubMed
    1. Chenivesse X, Franco D, Brechot C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J Hepatol. 1993;18:168–72. - PubMed
    1. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2010;596:47–76. - PubMed
    1. Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci USA. 2010;107:7449–54. - PMC - PubMed
    1. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265–83. - PubMed